

Substitute for form 1449A/PTO & 1449B/PTO				Complete if Known	
FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT				10/520626	
(use as many sheets as necessary)					
Sheet	1	of	2	Application Number	
				Filing Date	January 10, 2005
				First Named Inventor	Manuel Rosa-Calatrava et al.
				Examiner Name	
				Attorney Docket Number	017753-200

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/IP/	P. LEISSNER et al., "Influence of adenoviral fiber mutations on viral encapsidation, infectivity and <i>in vivo</i> tropism," GENE THERAPY, Macmillan Press Ltd., Basingstoke, GB, Vol. 8, No. 1, 2001, pp. 49-57
	D.A. EINFELD et al., "Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions," J. VIROL., Vol. 75, No. 23, December 2001, pp. 11284-11291
	M.C. DECHECCHI et al., "Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5," J. VIROL., Vol. 75, No. 18, September 2001, pp. 8772-8780
	M.C. DECHECCHI et al., "Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions," VIROLOGY, Academic Press, Orlando, FL, Vol. 268, No. 2, 15 March 2000, pp. 382-390
/IP/	M.J. VAN RAAIJ et al., "Structure of the human adenovirus serotype 2 fiber head domain at 1.5 Å resolution," VIROLOGY, Academic Press, Orlando, FL, Vol. 262, No. 2, 30 September 1999, pp. 333-343

Examiner Signature	/Ileana Popa/	Date Considered	06/26/2007
-----------------------	---------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Substitute for form 1449A/PTO & 1449B/PTO		Complete if Known	
FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>		10/520626	
Sheet	2	of	2
		Application Number	
		Filing Date	January 10, 2005
		First Named Inventor	Manuel Rosa-Calatrava et al.
		Examiner Name	
		Attorney Docket Number	017753-200

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/IP/	J.L. JAKUBCZAK et al., "Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells," JOURNAL OF VIROLOGY, Vol. 75, No. 6, March 2001, pp. 2972-2981
	I. KIRBY et al., "Identification of contact residues and definition of the Car-binding site of adenovirus type 5 fiber protein...", JOURNAL OF VIROLOGY, The American Society for Microbiology, US, Vol. 74, No. 6, March 2000, pp. 2804-2813
	I. KIRBY et al., "Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor car," JOURNAL OF VIROLOGY, The American Society for Microbiology, US, Vol. 73, No. 11, November 1999, pp. 9508-9514
/IP/	MONIKA: "Transductional targeting with recombinant adenovirus vectors," CURRENT GENE THERAPY, Vol. 2, No. 3, September 2002, pp. 323-339

Examiner Signature	/Ileana Popa/	Date Considered	06/26/2007
-----------------------	---------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.